| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Roemer Alan S. | Director | C/O IN8BIO, INC., 350 5TH AVE. SUITE 5330, NEW YORK | /s/ Jason Minio, Attorney-in-Fact | 2025-05-07 | 0001643070 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | INAB | Common Stock | Options Exercise | $18.9K | +102K | +35.95% | $0.18 | 387K | Apr 30, 2025 | Direct | |
| transaction | INAB | Common Stock | Options Exercise | $2.03K | +11K | +2.84% | $0.18 | 398K | Apr 30, 2025 | Direct |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | INAB | Series A Warrants (right to buy) | Disposed to Issuer | -102K | -100% | 0 | Apr 27, 2025 | Common Stock | 102K | $0.45 | Direct | F1, F2, F3 | ||
| transaction | INAB | Series A Warrants (right to buy) | Award | +102K | 102K | Apr 27, 2025 | Common Stock | 102K | $0.18 | Direct | F1, F2 | |||
| transaction | INAB | Series A Warrants (right to buy) | Options Exercise | $0 | -102K | -100% | $0.00 | 0 | Apr 30, 2025 | Common Stock | 102K | $0.18 | Direct | F2 |
| transaction | INAB | Series B Warrants (right to buy) | Disposed to Issuer | -102K | -100% | 0 | Apr 27, 2025 | Common Stock | 102K | $1.50 | Direct | F2, F3, F4 | ||
| transaction | INAB | Series B Warrants (right to buy) | Award | +11K | 11K | Apr 27, 2025 | Common Stock | 11K | $0.18 | Direct | F2, F4 | |||
| transaction | INAB | Series B Warrants (right to buy) | Options Exercise | $0 | -11K | -100% | $0.00 | 0 | Apr 30, 2025 | Common Stock | 11K | $0.18 | Direct | F2 |
| transaction | INAB | Series B Warrants (right to buy) | Award | +91.5K | 91.5K | Apr 27, 2025 | Common Stock | 91.5K | $0.45 | Direct | F2, F4, F5 |
| Id | Content |
|---|---|
| F1 | The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. |
| F2 | Fully vested and exercisable. |
| F3 | The reported securities are included within 102,459 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 102,459 shares of common stock. |
| F4 | The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share and expiration date of December 13, 2028. In regards to 11,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. In regards to the remaining 91,459 warrant shares, the exercise price was reduced to $0.45 per share with no change to the expiration date. |
| F5 | The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share. |